Egrifta (Tesamorelin) Patent Field & Generic Timeline

What Is Tesamorelin and How Does It Work?

Tesamorelin is a 44-amino-acid synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). It binds pituitary GHRH receptors with high affinity, stimulating pulsatile growth hormone (GH) secretion, which in turn raises insulin-like growth factor-1 (IGF-1) and drives lipolysis in visceral adipose tissue. The net clinical result in people with HIV-associated lipodystrophy is a meaningful, measurable reduction in abdominal fat without the supraphysiological GH exposure associated with exogenous recombinant GH therapy.

Structural Difference From Native GHRH

Native GHRH(1-44) degrades within minutes in plasma because dipeptidyl peptidase IV cleaves the Tyr-Ala bond at positions 1 and 2. Tesamorelin substitutes a trans-3-hexenoic acid moiety at the N-terminus, blocking that cleavage site. The half-life extends to roughly 26 minutes versus under 7 minutes for native GHRH, according to pharmacokinetic data reviewed in the FDA medical officer's report at the time of the 2010 NDA approval. [1]

Downstream GH and IGF-1 Effects

GH pulses stimulated by tesamorelin activate hormone-sensitive lipase in visceral adipocytes. IGF-1 rises modestly, typically by 80 to 140 ng/mL above baseline, as documented in the phase 3 trials. [2] Unlike supraphysiological exogenous GH, tesamorelin keeps GH within the normal 24-hour secretory arc, which is the mechanistic rationale for its more favorable glucose metabolism profile relative to direct GH administration. The FDA label notes that fasting glucose and HbA1c changes did not differ significantly from placebo in the key trials, though glucose monitoring is still warranted in patients with pre-existing diabetes. [3]

Why HIV Lipodystrophy Is the Target Indication

HIV-associated lipodystrophy affects an estimated 40 to 50% of people on long-term antiretroviral therapy (ART), particularly regimens containing thymidine-analogue nucleoside reverse-transcriptase inhibitors (tNRTIs) such as stavudine. [4] The visceral fat accumulation carries independent cardiovascular risk beyond the dyslipidemia already common in ART-treated patients. Tesamorelin addresses the fat redistribution specifically; it does not reduce peripheral lipoatrophy and is not indicated for general obesity.

FDA Approval History and Regulatory Milestones

Original Egrifta Approval (2010)

The FDA approved tesamorelin acetate under the brand name Egrifta on November 10, 2010, via NDA 022505. [5] The approval was based on two key phase 3 randomized controlled trials that together enrolled 816 HIV-positive adults. Falutz et al. (NEJM 2007, N=412) showed a 15.2% reduction in visceral adipose tissue (VAT) by CT scan in the tesamorelin arm versus 1.0% in the placebo arm at 26 weeks (P<0.0001). [2] A second confirmatory trial with similar design produced comparable results. [6]

Reformulated Egrifta SV (2019)

In 2019 the FDA approved a reformulated product, Egrifta SV (NDA 022505/S-012), requiring only a single-vial reconstitution step versus the two-vial process of the original formulation. [7] The reformulation uses a pH-adjusted acetate buffer that improves stability and simplifies administration. From a regulatory standpoint, the SV designation also reset certain exclusivity clocks, a detail with direct consequences for the generic timeline discussed later in this article.

REMS and Post-Market Requirements

The FDA did not require a Risk Evaluation and Mitigation Strategy (REMS) for tesamorelin, but post-market commitments included a long-term cardiovascular outcomes study and a 5-year pediatric investigation plan waiver. The absence of a REMS means generic applicants will not face REMS-sharing negotiation hurdles that complicate some other specialty drug genericizations. [8]

Mechanism at the Receptor Level

GHRH Receptor Binding Kinetics

The GHRH receptor (GHRHR) is a class B G-protein-coupled receptor expressed predominantly on pituitary somatotrophs. Tesamorelin binds GHRHR with a Ki of approximately 1 to 2 nM in radioligand binding assays, comparable to native GHRH(1-44). [9] Receptor activation triggers Gs-mediated cyclic AMP accumulation, protein kinase A activation, and downstream phosphorylation of the GH gene promoter, producing a GH pulse within 15 to 30 minutes of injection.

Somatostatin Counterbalance

Endogenous somatostatin tonically suppresses GH release between GHRH pulses. Tesamorelin, given as a once-daily subcutaneous bolus, mimics a natural GHRH pulse rather than providing continuous receptor stimulation. This pulse-rest pattern preserves somatostatin's inhibitory windows, reducing the risk of receptor desensitization and maintaining the normal GH feedback arc. A 2013 study in the Journal of Clinical Endocrinology and Metabolism confirmed that 26 weeks of daily tesamorelin did not blunt peak GH responses to a subsequent GHRH stimulation test. [10]

IGF-1 as a Safety Marker

The FDA label recommends IGF-1 monitoring during tesamorelin therapy. If IGF-1 rises above the age- and sex-adjusted upper limit of normal, the label advises dose interruption. [3] In the pooled phase 3 data, IGF-1 exceeded the upper normal limit in approximately 30% of tesamorelin-treated patients at some point during treatment, versus under 2% in the placebo group. [6]

Orange Book Patent Field

Patents Currently Listed (Mid-2025)

The FDA Orange Book lists the following patents for NDA 022505 (Egrifta SV) as of mid-2025:

| Patent Number | Expiry Date | Type | |---|---|---| | US 7,268,113 | October 2025 | Compound (peptide sequence) | | US 8,227,408 | June 2027 | Formulation | | US 10,736,944 | August 2027 | Method of use (HIV lipodystrophy) | | US 11,020,461 | June 2028 | Formulation (SV single-vial buffer) |

These dates reflect statutory expiry and do not account for any potential Patent Term Restoration under the Hatch-Waxman Act. Theratechnologies applied for patent term extension on the compound patent; if granted at the maximum 5-year extension, the compound patent could extend to 2030. [11]

Pediatric Exclusivity

The FDA granted Theratechnologies a 6-month pediatric exclusivity extension under FDAAA Section 505A, attached to the formulation patents, pushing effective market exclusivity out 6 months beyond their statutory expiry dates. [8] Pediatric exclusivity cannot be challenged through an ANDA paragraph IV certification; it runs automatically after the underlying patent expires.

New Chemical Entity Exclusivity

Because tesamorelin was approved as a new chemical entity (NCE) in 2010, it received 5-year NCE data exclusivity. That exclusivity expired in November 2015, meaning generic applicants could begin filing ANDAs after that date. [5] The NCE exclusivity bar has cleared. The remaining barrier is the Orange Book patent estate.

Generic Entry Timeline and Competitive Field

Paragraph IV Certification Status

As of mid-2025, no ANDA with a paragraph IV certification against Egrifta SV Orange Book patents has been publicly disclosed in FDA's Paragraph IV Certifications database. [12] The absence of filed paragraph IV certifications is notable. It may reflect the complexity of demonstrating bioequivalence for a peptide delivered by subcutaneous injection, the relatively small patient population (approximately 6,000 to 8,000 HIV-positive patients with documented lipodystrophy in the U.S.), or both.

Bioequivalence Challenges for Peptide Generics

Tesamorelin occupies a regulatory gray zone. It is a synthetic peptide (not a biologic under the Public Health Service Act definition of 351(i)), which means an ANDA pathway is theoretically available rather than the biosimilar 351(k) pathway. [13] Demonstrating bioequivalence to a peptide, however, requires characterizing primary sequence, secondary structure, and impurity profile at levels that approach biosimilar analytical standards. The FDA's 2018 Draft Guidance on Peptide Drug Products clarified that synthetic peptides of 40 or more amino acids face additional scrutiny comparable to biologics during the abbreviated approval process. [13] Tesamorelin, at 44 amino acids, sits just above that threshold.

Estimated Earliest Generic Window

Based on the current Orange Book patent estate and the absence of active paragraph IV litigation, the HealthRX medical team constructed the following decision framework for estimating generic entry:

Scenario A (No Litigation, Patents Expire Naturally): The last Orange Book patent (US 11,020,461) expires June 2028, plus 6 months pediatric exclusivity, placing the earliest uncontested generic launch at approximately December 2028. Under this scenario, the compound patent (US 7,268,113) expires October 2025, opening a narrow window for an ANDA filer to challenge only the formulation patents.

Scenario B (Successful Paragraph IV Challenge on Formulation Patents): A generic filer files an ANDA with paragraph IV certification against the 2027 formulation patent, arguing non-infringement or invalidity. If litigation resolves favorably within the 30-month stay period, a generic could theoretically launch as early as late 2027. The 180-day first-filer exclusivity would reward that challenger.

Scenario C (Regulatory Reclassification as Biologic): If the FDA reclassifies tesamorelin as a biologic under the BPCIA, any follow-on product would require the 351(k) biosimilar pathway, adding 12 years of reference product exclusivity from the date of reclassification. Given that the FDA has not signaled reclassification intent as of mid-2025, this scenario remains low-probability in the near term.

The most likely commercial generic entry window, absent litigation surprises, is late 2028 to early 2029.

Clinical Efficacy Data That Generics Must Match

Primary Endpoint: VAT Reduction

Falutz et al. (NEJM 2007, N=412) randomized HIV-positive adults with abdominal lipodystrophy to tesamorelin 2 mg subcutaneous daily or placebo for 26 weeks. [2] The tesamorelin group reduced trunk fat by a mean of 15.2% versus 1.0% in placebo. VAT was measured by CT at L4-L5. The between-group difference of 14.2 percentage points was statistically significant (P<0.0001).

A second phase 3 trial (N=404) replicated the finding: the tesamorelin arm achieved a 17.8% VAT reduction versus 2.0% in placebo at 26 weeks. [6] Both trials included a 26-week extension period. In the extension, patients re-randomized from tesamorelin to placebo regained approximately half of the VAT reduction within 26 weeks, confirming the effect is treatment-dependent and not sustained without ongoing therapy.

Secondary Endpoints: Metabolic and Body Composition Effects

Total cholesterol and triglycerides fell modestly in the tesamorelin group. A 2014 analysis published in Clinical Infectious Diseases (N=816 pooled) reported a mean triglyceride reduction of 19.8 mg/dL in tesamorelin-treated patients versus a 7.2 mg/dL reduction in placebo (P<0.05). [14] Lean body mass did not change significantly, and limb fat did not improve, confirming the mechanism targets visceral rather than subcutaneous or peripheral adipose tissue.

Patient-Reported Outcomes

The trials used the Lipodystrophy-Specific Self-Assessment (LSSA) questionnaire, a validated instrument for HIV body-image disturbance. Tesamorelin-treated patients reported a statistically significant improvement in body image at 26 weeks versus placebo. [2] This outcome is relevant for FDA's determination of clinical meaningfulness and will be required of any generic or follow-on applicant seeking the same labeling claim.

Safety Profile and Monitoring Requirements

Common Adverse Events

In pooled phase 3 data, the most common adverse events in the tesamorelin arm were injection-site reactions (25.4% vs. 6.5% placebo), arthralgia (13.3% vs. 7.0% placebo), and peripheral edema (6.9% vs. 2.5% placebo). [3] These events are consistent with GH axis activation and fluid retention. Most resolved within the first 12 weeks without dose adjustment.

Glucose Metabolism

The FDA label carries a warning about potential impairment of glucose tolerance. [3] In the pooled trials, new-onset diabetes occurred in 3.9% of tesamorelin-treated patients versus 1.4% of placebo patients over 52 weeks. [6] Clinicians should obtain a fasting glucose and HbA1c at baseline and every 6 months during therapy, consistent with the Endocrine Society's 2011 clinical practice guideline on growth hormone deficiency, which recommends glucose monitoring for all GH-axis therapies. [15]

Contraindications

Tesamorelin is contraindicated in active malignancy, pituitary tumor, pregnancy, and hypersensitivity to tesamorelin or mannitol (an excipient). [3] The pregnancy contraindication is absolute because GHRH-axis stimulation during organogenesis carries unknown fetal risk and growth disturbance potential.

What Prescribers and Patients Should Know About the Generic Timeline

Cost Implications While Patent-Protected

Egrifta SV carries a wholesale acquisition cost of approximately $5,000 to $6,500 per month as of 2024 pricing. No authorized generic exists. Patients who cannot access manufacturer co-pay assistance (Theratechnologies' EGRIFTA Access Program) face substantial out-of-pocket costs, particularly under high-deductible health plans or Medicare Part D benefit designs before catastrophic coverage kicks in.

Compounded Tesamorelin

Compounding pharmacies produce tesamorelin outside the FDA-approved supply chain. The FDA has not approved any compounded tesamorelin product, and compounded versions are not required to demonstrate bioequivalence. [16] Prescribers should document informed consent discussions about the unknown quality, potency consistency, and sterility standards of compounded peptides when considering this route for cost-sensitive patients.

Monitoring While Awaiting Generic Access

Patients who begin Egrifta SV and then lose insurance coverage face a clinical dilemma: discontinuation leads to VAT rebound within 6 months, as the extension-phase data confirm. [2] Clinicians should establish a monitoring plan that tracks IGF-1 every 6 months, fasting glucose every 6 months, and VAT by CT or waist circumference proxy at 26-week intervals. [15]

Tesamorelin Beyond HIV Lipodystrophy: Pipeline and Off-Label Use

Non-Alcoholic Fatty Liver Disease (NAFLD)

A 2019 randomized trial published in Hepatology (N=61) evaluated tesamorelin 2 mg daily for 12 months in HIV-positive adults with NAFLD. [17] Liver fat fraction by MR spectroscopy fell by 37% in the tesamorelin arm versus 4% in placebo (P<0.01). This signal is the basis for Theratechnologies' ongoing Investigational New Drug work for a potential NAFLD indication, which, if approved, would generate new Orange Book listings and extend the exclusivity runway further.

Cognitive Function in Older Adults

A National Institutes of Health-funded trial at Washington University (N=152, NCT01915342) tested tesamorelin versus placebo in older adults without HIV to assess effects on cognition and brain amyloid. [18] The trial did not demonstrate a statistically significant difference in the primary cognitive endpoint at 20 months. Tesamorelin is not approved and has no regulatory pathway currently open for this indication.

Implications for Generic Filers

New indications under supplemental NDAs generate additional method-of-use patents listed in the Orange Book. A NAFLD supplemental approval, if granted, would add new patents that generic ANDA filers would need to carve out via a "skinny label" strategy, limiting the generic to the HIV lipodystrophy indication only. Generic sponsors monitoring this pipeline should track IND and NDA filings for tesamorelin in NAFLD through the FDA's Drug Trials Snapshots database. [19]

Competitive Products and Market Context

No other FDA-approved drug shares the exact tesamorelin mechanism for HIV lipodystrophy. Metformin reduces visceral fat modestly in HIV-positive patients but lacks FDA approval for this indication. [20] Recombinant human GH (somatropin, brand: Serostim) is approved for HIV wasting (not lipodystrophy) and carries a higher risk of glucose dysregulation at therapeutic doses. Tesamorelin's specificity for the GHRH receptor, preserving the natural GH pulsatility arc, differentiates it mechanistically from direct GH replacement.

The small market size (approximately 6,000 to 8,000 treated U.S. Patients) limits generic manufacturer return on investment for a product requiring complex peptide synthesis and cold-chain logistics. This commercial calculus partly explains why no ANDA has been filed despite the NCE exclusivity having expired in 2015.